Scientific Opinion on the risks for public health related to the presence of opium alkaloids in poppy seeds

EFSA Journal

Volumn 9, Issue 11, 2011, Pages

[No Author Info available]

Author keywords

acute reference dose (ARfD); codeine; dietary exposure; morphine; pharmacology; poppy seeds; toxicity

Indexed keywords

EID: 85058651530     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2011.2405     Document Type: Article

References (280)

1. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A and Bui C, 2003. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ, 327, 523–528.
2. Acosta D, Anuforo DC and Smith RV, 1980. Cytotoxicity of acetaminophen and papaverine in primary cultures of rat hepatocytes. Toxicology and Applied Pharmacology, 53, 306–314.
3. Adams ML, Sewing B, Forman JB, Meyer ER and Cicero TJ, 1993. Opioid-induced suppression of rat testicular function. The Journal of Pharmacology and Experimental Therapeutics, 266, 323–328.
4. Adler TK, Fujimoto JM, Way EL and Baker EM, 1955. The metabolic fate of codeine in man. The Journal of Pharmacology and Experimental Therapeutics, 114, 251–262.
5. AHFS (American Hospital Formulary Service), 1995. American Hospital Formulary Service. Ed McEvoy GK. American Society of Health-System Pharmacists. 7272 Wisconsin Avenue, Bethesda, MD 20814.
6. AHFS (American Hospital Formulary Service), 2007. AHFS Drug Information, 2007. American Hospital Formulary Service. Ed McEvoy GK. American Society of Health-System Pharmacists. 7272 Wisconsin Avenue, Bethesda, MD 20814.
7. th edition, Elsevier, München, Germany.
8. Amann T and Zenk MH, 1996. Endogenes Morphin. Deutsche Apotheker Zeitung, 136, 17–25.
9. Andresen H and Schmoldt A, 2004. Führt der Verzehr von Mohnsamen zu positiven Opiatbefunden in Urin, Blut und Haaren? Blutalkohol, 4, 191–202.
10. Aneja R, Dhiman N, Idnani J, Awasthi A, Arora SK, Chandra R and Joshi HC, 2007. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemotherapy and Pharmacology, 60, 831–839.
11. Anonymous, 2011. Poppy Seed Oil. Available from www.recipetips.com/glossary-term/t-36310/poppy-seed-oil.asp. Retrieved on 12.04.2011.
12. Argoff CE and Silvershein DI, 2009. A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clinic Proceedings, 84, 602–612.
13. Armstrong SC and Cozza KL, 2003. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: Theory and clinical reality, part I. Psychosomatics, 44, 167–171.
14. Azcan N, Kalender BO and Kara M, 2004. Investigation of Turkish poppy seeds and seed oils. Chemistry of Natural Compounds, 40, 370–372.
15. Badr FM and Rabouh SA, 1983. Effects of morphine-sulfate on the germ-cells of male-mice. Teratogenesis Carcinogenesis and Mutagenesis, 3, 19–26.
16. Bandstra ES, Morrow CE, Mansoor E and Accornero VH, 2010. Prenatal drug exposure: infant and toddler outcomes. Journal of Addictive Diseases, 29, 245–258.
17. Barnes PJ and Chung KF, 1989. Difficult asthma. BMJ, 299, 695–698, author reply 1031-1032.
18. rd edition. Chicago. Year Book Medical Publishers Inc.
19. Belpaire FM, Rosseel MT and Bogaert MG, 1978. Metabolism of papaverine IV. Urinary elimination of papaverine metabolites in man. Xenobiotica, 8, 297–300.
20. Berényi S, Csutorás C and Sipos A, 2009. Recent developments in the chemistry of thebaine and its transformation products as pharmacological targets. Current Medicinal Chemistry, 16, 3215–3242.
21. Bergstrom L, 1994. Nutrient Losses and Gains in the Preparation of Foods. Livsmedelsverket Rapport 32/94.
22. Bernáth J, 1998. Poppy: the genus Papaver. Series: Medicinal and Aromatic Plants-Industrial Profiles. Ed Bernáth J. Harwood Academic Publishers, Amsterdam, The Netherlands.
23. Bernáth J, Dános B, Veres T, Szántó J and Tétényi P, 1988. Variation in alkaloid production in poppy ecotypes-responses to different environments. Biochemical Systematics and Ecology, 16, 171–178.
24. Bernáth J and Németh E, 2009. Poppy, Oil Crops. Handbook of Plant Breeding 4. Eds Vollmann J and Rajcan I. Springer Science and Business Media, 449–468.
25. Bernáth J and Németh E, 2010. A mák. Termesztés és receptek. CSER, Kiadó. Budapest. 88 pp.
26. Berrill JW and Linnasne SJ, 2003. Morphine for management of refractory dyspnoea: opiates should be used with caution. BMJ, 327, 1288; author reply 1288-1289.
27. BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte-Federal Institute for Drugs and Medical Devices), 2004. Fachinformationen, Mustertexte: Morphin, Lösung, Filmtablette, Brausetablette. Available from www.bfarm.de.
28. BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte-Federal Institute for Drugs and Medical Devices), 2005. Fachinformationen, Mustertexte: Morphin Retardtablette, Retardkapsel, Retardgranulat. Available from www.bfarm.de.
29. 2O; Codeinphosphat. Available from www.bfarm.de.
30. BfR (Bundesinstitut für Risikobewertung-Federal Institute for Risk Assessment), 2005a. BfR recommends provisional daily upper intake level and a guidance value for morphine in poppy seeds, BfR Health Assessment No. 012/2006, 27 December 2005. Available from www.bfr.bund.de/cm/245/bfr_recommends_provisional_daily_upper_intake_level_and_a_guidance_value_for_morphine_in_poppy_seeds.pdf.
31. BfR (Bundesinstitut für Risikobewertung-Federal Institute for Risk Assessment), 2005b. Backmohn ist kein Schlafmittel für Säuglinge; BfR-Pressemitteilung Nr. 12 vom 29.04.2005.
32. Biruté I, 1998. Lithuanian Traditional Foods. Ed Biruté I. Baltos Lankos, Lithuania. 109 pp.
33. Bjerver K, Jonsson J, Nilsson A and Schuberth J, 1982. Morphine intake from poppy seed food. Journal of Pharmacy and Pharmacology, 34, 798–801.
34. Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J and Schulz V, 2003. Hager ROM 2003. Hagers Handbuch der Drogen und Arzneistoffe. Springer0 Medizin Verlag, Heidelberg.
35. Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J and Schulz V, 2006. Hager ROM 2006. Hagers Handbuch der Drogen und Arzneistoffe. Springer Medizin Verlag, Heidelberg.
36. Blaschek W, Hänsel R, Keller K, Reichling J, Rimpler H and Schneider G, 1998. Hagers Handbuch 5. Auflage, Springer Medizin Verlag, Heidelberg.
37. Borgbjerg FM, Nielsen K and Franks J, 1996. Experimental pain stimulates respiration and attenuates morphine-induced respiratory depression: a controlled study in human volunteers. Pain, 64, 123–128.
38. Bosch ME, Sanchez AR, Rojas FS and Ojeda CB, 2007. Morphine and its metabolites: analytical methodologies for its determination. Journal of Pharmaceutical and Biomedical Analysis, 43, 799–815.
39. Boyd KJ and Kelly M, 1997. Oral morphine as symptomatic treatment of dyspnoea in patients with advanced cancer. Palliative Medicine, 11, 277–281.
40. 2. Journal of Food Science, 68, 422–426.
41. Bracher F, Heisig P, Langguth P, Mutschler E, Rücker G, Scriba G, Stahl-Biskup E and Troschütz R, 2004. Kommentar zum Europäischen Arzneibuch (Commentary to the Pharmacopoeia Europaea), Wissenschaftliche Verlagsgesellschaft, Stuttgart, Germany.
42. Bracher F, Heisig P, Langguth P, Mutschler E, Rücker G, Scriba G, Stahl-Biskup E and Troschütz R, 2010. Kommentar zum Europäischen Arzneibuch (Commentary to the Pharmacopoeia Europaea), Wissenschaftliche Verlagsgesellschaft, Stuttgart, Germany.
43. Bracken MB and Holford TR, 1981. Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstetrics and Gynecology, 58, 336–344.
44. Bratina A, Perpar M and Tišler M, 1957. Beitrag zur Bestimmung von Morphin in Mohnkapseln. Microchimica Acta, 45, 167–173.
45. Braye K, Harwood T, Inder R, Beasley R and Robinson G, 2007. Poppy seed tea and opiate abuse in New Zealand. Drug and Alcohol Review, 26, 215–219.
46. Briggs GG, Freeman RK and Sumner JY, 1986. Drugs in pregnancy and lactation. 2nd ed. Williams & Wilkins. 102–103c.
47. Brown KA, Laferriere A, Lakheeram I and Moss IR, 2006. Recurrent hypoxemia in children is associated with increased analgesic sensitivity to opiates. Anesthesiology, 105, 665–669.
48. Brunk SF and Delle M, 1974. Morphine metabolism in man. Clinical Pharmacology and Therapeutics, 16, 51–57.
49. Brunton LL, Lazo JS, Parker KL and Gilman AG, 2006. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11thed. McGraw-Hill, New York.
50. Bryant HU and Holaday JW, 1993. Opioids in immunologic Processes. In: Opioids II, Handbook of Experimental Pharmacology. Ed Herz A. Springer-Verlag, Berlin, 361–392.
51. Caldwell JR, Rapoport RJ, Davis JC, Offenberg HL, Marker HW, Roth SH, Yuan W, Eliot L, Babul N and Lynch PM, 2002. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. Journal of Pain and Symptom Management, 23, 278–291.
52. Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain, 2010. National Opioid Use Guideline Group (NOUGG), Part A and B. April 30, 2010.
53. Caraco Y, Sheller J and Wood AJ, 1999. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. The Journal of Pharmacology and Experimental Therapeutics, 290, 413–422.
54. Carbajal R and Simon N, 1995. Sedation and analgesia in children. Archives de Pediatrie, 2, 1089–1096.
55. Chapman SL, Byas-Smith MG and Reed BA, 2002. Effects of intermediate- and long-term use of opioids on cognition in patients with chronic pain. The Clinical Journal of Pain, 18, S83–90.
56. Chen ZR, Irvine RJ, Somogyi AA and Bochner F, 1991. Mu receptor binding of some commonly used opioids and their metabolites. Life Sciences, 48, 2165–2171.
57. Cicero TJ, Meyer ER, Bell RD and Koch GA, 1976. Effects of morphine and methadone on serum testosterone and luteinizing hormone levels and on the secondary sex organs of the male rat. Endocrinology, 98, 367–372.
58. Ciszkowski C, Madadi P, Phillips MS, Lauwers AE and Koren G, 2009. Codeine, ultrarapid-metabolism genotype, and postoperative death. The New England Jornal of Medicine, 361, 827–828.
59. Cobrinik RW, Hood RT, Jr. and Chusid E, 1959. The effect of maternal narcotic addiction on the newborn infant; review of literature and report of 22 cases. Pediatrics, 24, 288–304.
60. Coffman BL, King CD, Rios GR and Tephly TR, 1998. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metabolism and Disposition, 26, 73–77.
61. Collins LR, Hall RW, Dajani NK, Wendel PJ, Lowery CL and Kay HH, 2005. Prolonged morphine exposure in utero causes fetal and placental vasoconstriction: a case report. The Journal of Maternal-Fetal & Neonatal Medicine, 17, 417–421.
62. Couch DB and Sawant SG, 1995. The clastogenicity of morphine sulfate in vivo. Brain Immune Axis and Substance Abuse, 373, 123–129.
63. Cowan A, 1993. Effects of Opioids on the spontaneous Behavior of Animals. In: Opioids II, Handbook of Experimental Pharmacology. Ed Herz A. Springer-Verlag, Berlin, 393–428.
64. Crivellaro M, Bonadonna P, Dama A, Senna GE, Mezzelani P, Mistrello G and Passalacqua G, 1999. Severe systemic reactions caused by poppy seed. Journal of Investigational Allergology & Clinical Immunology, 9, 58–59.
65. Currow DC, McDonald C, Oaten S, Kenny B, Allcroft P, Frith P, Briffa M, Johnson MJ and Abernethy AP, 2011. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. Journal of Pain and Symptom Management, 42, 388–399.
66. Dahlheim M, Schwartz T and Banffy-Josika E, 2010. Nichtinterventionelle multizentrische Studie zur Therapie des unproduktiven Reizhustens mit Noscapin im Vergleich zu Codein/Dihydrocodein (Non-interventional multicentre study on the treatment of unproductive dry cough with noscapine versus codeine/dihydrocodeine). Atemwegs- und Lungenkrankheiten, 36, 35–40.
67. Dahlström B, Mellstrand T, Lofdahl CG and Johansson M, 1982. Pharmacokinetic properties of noscapine. European Journal of Clinical Pharmacology, 22, 535–539.
68. Davila JC, Reddy CG, Davis PJ and Acosta D, 1990. Toxicity assessment of papaverine hydrochloride and papaverine-derived metabolites in primary cultures of rat hepatocytes. In Vitro Cellular & Developmental Biology, 26, 515–524.
69. nd edition. Eds Fallon M and Hanks G. BMJ Publishing Group, London, 13–16.
70. De Jong TR, Veening JG, Olivier B and Waldinger MD, 2007. Oxytocin involvement in SSRI-induced delayed ejaculation: a review of animal studies. The Journal of Sexual Medicine, 4, 14–28.
71. De Waal EJ, Van Der Laan JW and Van Loveren H, 1998. Effects of prolonged exposure to morphine and methadone on in vivo parameters of immune function in rats. Toxicology, 129, 201–210.
72. Dejnega D, Girsch L and Kramberger I, 2002. Betrachtungen zur Saatgutproduktion und zu Saatgutregelungen bei Mohn (Papaver somniferum L.); AGES-Österreichische Agentur für Gesundheit und Ernährungs-sicherheit GmbH / Institut für Saatgut, Wien.
73. Dillenburg CF, Kruel CD, Cerski CT, Edelweiss MI, Silva TL and Schier AS, 2008. Morphine does no promote esophageal carcinogenesis in rats exposed to diethylnitrosamine. Arquivos de Gastroenterologia, 45, 87–92.
74. Dimsdale JE, Norman D, DeJardin D and Wallace MS, 2007. The effect of opioids on sleep architecture. Journal of Clinical Sleep Medicine, 3, 33–36.
75. Dittbrenner A, Mock HP, Borner A and Lohwasser U, 2009. Variability of alkaloid content in Papaver somniferum L. Journal of Applied Botany and Food Quality-Angewandte Botanik, 82, 103–107.
76. Donahoe RM, Madden JJ, Hollingsworth F, Shafer D and Falek A, 1985. Morphine depression of T cell E-rosetting: definition of the process. Federation Proceedings, 44, 95–99.
77. Donnerer J, Oka K, Brossi A, Rice KC and Spector S, 1986. Presence and formation of codeine and morphine in the rat. Proceedings of the National Academy of Sciences of the United States of America, 83, 4566–4567.
78. Dusemund B, Appel K-E and Lampen A, 2010. BfR risk assessment of alkaloids as ingredients and contaminants of food: Quinine, opium alkaloids, and senecio pyrrolizidine alkaloids. In: Risk Assessment of Phytochemicals in Food. Ed DFG Senate commission on Food safety (SKLM). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 382–390.
79. Ebbighausen WOR, Mowat J and Vestergaard P, 1973. Mass fragmentographic detection of normorphine in urine of man after codeine intake. Journal of Pharmaceutical Sciences, 62, 146–148.
80. Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N and Mikus G, 2000. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesthesia and Analgesia, 91, 185–191.
81. Edginton AN, Schmitt W and Willmann S, 2006. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clinical Pharmacokinetics, 45, 1013–1034.
82. EFSA (European Food Safety Authority), 2006. Guidance of the Scientific Committee on a request from EFSA related to Uncertainties in Dietary Exposure Assessment. The EFSA Journal, 438, 1–54.
83. EFSA (European Food Safety Authority), 2011a. Evaluation of the FoodEx, the food classification system applied to the development of the EFSA Comprehensive European Food Consumption Database. EFSA Journal 2011; 9(3):1970. 27 pp.
84. EFSA (European Food Safety Authority), 2011b. Use of the EFSA Comprehensive European Food Consumption Database in Exposure Assessment. EFSA Journal 2011;9(3):2097. 2097, 34 pp.
85. Eisinger DA and Ammer H, 2011. Epidermal growth factor treatment switches delta-opioid receptor-stimulated extracellular signal-regulated kinases 1 and 2 signaling from an epidermal growth factor to an insulin-like growth factor-1 receptor-dependent mechanism. Molecular Pharmacology, 79, 326–335.
86. Falek A, Jordan RB, King BJ, Arnold PJ and Skelton WD, 1972. Human chromosomes and opiates. Archives of General Psychiatry, 27, 511–515.
87. Farney RJ, Walker JM, Cloward TV and Rhondeau S, 2003. Sleep-disordered breathing associated with long-term opioid therapy. Chest, 123, 632–639.
88. Feilberg VL, Rosenborg D, Broen Christensen C and Mogensen JV, 1989. Excretion of morphine in human breast milk. Acta Anaesthesiologica Scandinavica, 33, 426–428.
89. Fist AJ, Byrne CJ and Gerlach WL, 2000. United States Patent Number 6,067,749, Papaver somniferum strain with high concentration of thebaine and oripavine, May 30, 2000.
90. Forth W, Henschler D, Rummel W, Förstermann U and Starke K, 2001. Allgemeine und spezielle Pharmakologie und Toxikologie. Urban & Fischer München, Jena, 8. vollständig überarbeitete Aufl., S. 564.
91. Frantzen B, Bröcker EB and Trautmann A, 2000. Immediate-type allergy caused by poppy seed. Allergy, 55, 97–98.
92. Frenk H, 1983. Pro- and anticonvulsant actions of morphine and the endogenous opioids: involvement and interactions of multiple opiate and non-opiate systems. Brain Research, 287, 197–210.
93. Frohne D and Pfänder HJ, 1987. Giftpflanzen; 3. Auflage, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart.
94. Frohne D and Pfänder HJ, 2004. Giftpflanzen; 5. Auflage, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart.
95. Frölich N, Dees C, Paetz C, Ren X, Lohse MJ, Nikolaev VO and Zenk MH, 2011. Distinct pharmacological properties of morphine metabolites at G(i)-protein and beta-arrestin signaling pathways activated by the human mu-opioid receptor. Biochemical Pharmacology, 81, 1248–1254.
96. Fujinaga M and Mazze RI, 1988. Teratogenic and postnatal developmental studies of morphine in Sprague-Dawley rats. Teratology, 38, 401–410.
97. Gatehouse DG, Stemp G, Pascoe S, Wilcox P, Hawker J and Tweats DJ, 1991. Investigations into the induction of aneuploidy and polyploidy in mammalian cells by the anti-tussive agent noscapine hydrochloride. Mutagenesis, 6, 279–283.
98. Geber WF and Schramm LC, 1975. Congenital malformations of the central nervous system produced by narcotic analgesics in the hamster. American Journal of Obstetrics and Gynecology, 123, 705–713.
99. General J, Unbehend G, Lindhauer MG, Kniel B and Moser M, 2007. Untersuchungen zur Reduzierung von Morphin in Mohnsamen und Mohngebäcken mit praktikablen technologischen Massnahmen. Getreidetechnologie, 61, 36–42.
100. Gessner O, 1974. Gift- und Arzneipflanzen von Mitteleuropa; 3. Auflage, Carl Winter Universitätsverlag, Heidelberg.
101. th ed. Eds Goodman and Gilman's. MacMillan Publishing Co., New York, 1985.
102. Golianu B, Krane EJ, Galloway KS and Yaster M, 2000. Pediatric acute pain management. Pediatric Clinics of North America, 47, 559–587.
103. Grove MD, Spencer GF, Wakeman MV and Tookey HL, 1976. Morphine and codeine in poppy seed. Journal of Agricultural and Food Chemistry, 24, 896–897.
104. Hanks GW, 1995. Morphine sans morpheus. Lancet, 346, 652–653.
105. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Casas JR, Sawe J, Twycross RG and Ventafridda V, 2001. Morphine and alternative opioids in cancer pain: the EAPC recommendations. British Journal of Cancer, 84, 587–593.
106. Hanks GW, Twycross RG and Lloyd JW, 1981. Unexpected complication of successful nerve block. Morphine induced respiratory depression precipitated by removal of severe pain. Anaesthesia, 36, 37–39.
107. Hanks GW, 1989. Controlled-release morphine (MST contin) in advanced cancer-The European experience. Cancer, 63, 2378–2382.
108. Hänsel R, Sticher O and Steinegger E, 1999. Pharmakognosie-Phytopharmazie; 6. Auflage, Springer Verlag, Heidelberg.
109. th edition, McGraw-Hill.
110. Harpel HS, Jr. and Gautieri RF, 1968. Morphine-induced fetal malformations. I. Exencephaly and axial skeletal fusions. Journal of Pharmaceutical Sciences, 57, 1590–1597.
111. Hartel CR, Woods JH and Schuster CR, 1981. Behavioral effects of thebaine in the rhesus monkey. Pharmacology Biochemistry and Behavior, 14, 805–809.
112. Hayes LW, Krasselt WG and Mueggler PA, 1987. Concentrations of morphine and codeine in serum and urine after ingestion of poppy seeds. Clinical Chemistry, 33, 806–808.
113. Heinonen OP, Slone D and Shapiro S, 1977. Birth Defects and Drugs in Pregnancy. Littleton, Massachusetts. Publishing Sciences Group. 287–295.
114. Hill V, Cairns T, Cheng CC and Schaffer M, 2005. Multiple aspects of hair analysis for opiates: methodology, clinical and workplace populations, codeine, and poppy seed ingestion. Journal of Analytical Toxicology, 29, 696–703.
115. Hoppe HA, 1975. Drogenkunde, Band 1, Angiospermen, 8. Auflage, Walter de Gruyter Verlag, Berlin.
116. Huybrechts I, Sioen I, Boon PE, Ruprich J, Lafay L, Turrini A, Amiano P, Hirvonen T, De Neve M, Arcella D, Moschandreas J, Westerlund A, Ribas-Barba L, Hilbig A, Papoutsou S, Christensen T, Oltarzewski M, Virtanen S, Rehurkova I, Azpiri M, Sette S, Kersting M, Walkiewicz A, Serra-Majem L, Volatier JL, Trolle E, Tornaritis M, Busk L, Kafatos A, Fabiansson S, De Henauw S and Van Klaveren J, in press. Dietary Exposure Assessments for Children in Europe (the EXPOCHI project): rationale, methods and design. Archives of Public Health, in press.
117. IPCS (International Programme on Chemical Safety), 1990. Codeine. Available from www.inchem.org/documents/pims/pharm/codeine.htm.
118. Ishidate M, Jr., Hayashi M, Sawada M, Matsuoka A, Yoshikawa K, Ono M and Nakadate M, 1978. Cytotoxicity test on medical drugs-chromosome aberration tests with Chinese hamster cells in vitro (author's transl). Eisei Shikenjo Hokoku, 55–61.
119. Iwamoto K and Klaassen CD, 1977. 1st-pass effectt of morphine in rats. Journal of Pharmacology and Experimental Therapeutics, 200, 236–244.
120. Jansson LM, Velez M and Harrow C, 2009. The opioid-exposed newborn: assessment and pharmacologic management. Journal of Opioid Management, 5, 47–55.
121. Jennings AL, Davies AN, Higgins JP, Gibbs JS and Broadley KE, 2002. A systematic review of the use of opioids in the management of dyspnoea. Thorax, 57, 939–944.
122. Johnson MJ, McDonagh TA, Harkness A, McKay SE and Dargie HJ, 2002. Morphine for the relief of breathlessness in patients with chronic heart failure-a pilot study. European Journal of Heart Failure, 4, 753–756.
123. Jurand A, 1985. The interference of naloxone hydrochloride in the teratogenic activity of opiates. Teratology, 31, 235–240.
124. Kadar I, Foldesi D, Voros J, Szilagyi J and Lukacs D, 2001. Mineral fertilisation of poppy (Papaver somniferum L.) on calcareous loamy chernozem soil. II. Novenytermeles, 50, 467–468.
125. Kalvass JC, Olson ER, Cassidy MP, Selley DE and Pollack GM, 2007. Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data. The Journal of Pharmacology and Experimental Therapeutics, 323, 346–355.
126. Karlsson MO and Dahlstrom B, 1990. Serum protein binding of noscapine: influence of a reversible hydrolysis. The Journal of Pharmacy and Pharmacology, 42, 140–143.
127. Keskin O and Sekerel BE, 2006. Poppy seed allergy: a case report and review of the literature. Allergy and Asthma Proceedings, 27, 396–398.
128. Kharasch ED, Hoffer C, Whittington D and Sheffels P, 2003. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clinical Pharmacology and Therapeutics, 74, 543–554.
129. Khera KS, 1984. Maternal toxicity-a possible factor in fetal malformations in mice. Teratology, 29, 411–416.
130. Kiang TKL, Ensom MHH and Chang TKH, 2005. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacology & Therapeutics, 106, 97–132.
131. King MA, McDonough MA, Drummer OH and Berkovic SF, 1997. Poppy tea and the baker's first seizure. Lancet, 350, 716.
132. Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lotsch J, Roots I and Brockmoller J, 2007. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. The Pharmacogenomics Journal, 7, 257–265.
133. Klepstad P, Kaasa S, Jystad A, Hval B and Borchgrevin PC, 2003. Immediate- or sustained-release morphine for dose finding during start of morphine to cancer patients: a randomized, double-blind trial. Pain, 101, 193–198.
134. Knibbe CA, Krekels EH, van den Anker JN, DeJongh J, Santen GW, van Dijk M, Simons SH, van Lingen RA, Jacqz-Aigrain EM, Danhof M and Tibboel D, 2009. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clinical Pharmacokinetics, 48, 371–385.
135. Kodaira H and Spector S, 1988. Transformation of thebaine to oripavine, codeine, and morphine by rat liver, kidney, and brain microsomes. Proceedings of the National Academy of Sciences of the United States of America, 85, 1267–1271.
136. Koehler U, Augsten M, Cassel W, Jerrentrup A, Nolte J and Dette F, 2010. Sleep-disordered breathing in long-term opioid therapy. Deutsche Medizinische Wochenschrift, 135, 1125–1128.
137. Konzett H, 1955. Neure Gesichspunkte zur Pharmakologie des Narkotins (New viewpoints in the pharmacology of narcotine). Wiener Klinische Wochenschrift, 67, 306–309.
138. Kopecky EA, Ryan ML, Barrett JF, Seaward PG, Ryan G, Koren G and Amankwah K, 2000. Fetal response to maternally administered morphine. American Journal of Obstetrics and Gynecology, 183, 424–430.
139. Koren G, Cairns J, Chitayat D, Gaedigk A and Leeder SJ, 2006. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet, 368, 704.
140. Kress HG and Kraft B, 2005. Opioid medication and driving ability. European Journal of Pain, 9, 141–144.
141. Krueger HM, Eddy NB and Sumwalt M, 1943. Morphine. Part I, and Other Alkaloids. Part II. In: The Pharmacology of the Opium Alkaloids. Supplement no. 165 Public Health Reports. Washington D.C.: US Government Printing Office.
142. Lachenmeier DW, Sproll C and Musshoff F, 2010. Poppy seed foods and opiate drug testing-where are we today? Therapeutic Drug Monitoring, 32, 11–18.
143. Lachman J, Hejtmánková A, Miholová D, Kolihová D and Tluka P, 2006. Relations among alkaloids, cadmium and zinc contents in opium poppy (Papaver somniferum L.) Plant, Soil and Environment, 52, 282–288.
144. Larsen B, Otto H, Dorscheid E and Larsen R, 1999. Effects of long-term opioid therapy on psychomotor function in patients with cancer pain or non-malignant pain. Anaesthesist, 48, 613–624.
145. Lasagna L, Owens AH, Shnider BI and Lennard Gold G, 1961. Toxicity after large doses of noscapine. Cancer Chemotherapy Reports, 15, 33–34.
146. Lefkowitz SS and Chiang CY, 1975. Effects of certain abused drug s on hemolysin forming cells. Life Sciences, 17, 1763–1767.
147. Lehman VH, 1976. Teratologic studies in rabbits and rats with the morphine derivate codeine. Arzneimittelforschung, 26, 551–554.
148. Lehoczky Z, 1970a. Die Toxizität von Bencyclan und Papaverin an Ratten. Eine vergleichende Untersuchung uber 45 Tage (The toxicity of bencyclane and papaverine in rats. A comparative study over 45 days). Arzneimittelforschung, 20, 1394–1936.
149. Lehoczky Z, 1970b. Die Toxizitat von Bencyclan und Papaverin an Hunden. Eine vergleichende Untersuchung uber 6 Monate (The toxicity of bencyclane and papaverine in dogs. A comparative study over 6 months). Arzneimittelforschung, 20, 1396–1398.
150. Leverge R, Bergmann JF, Simoneau G, Tillet Y and Bonnemain B, 2003. Bioavailability of oral vs intramuscular iodinated oil (Lipiodol UF) in healthy subjects. Journal of Endocrinological Investigation, 26, 20–26.
151. Li JH and Lin LF, 1998. Genetic toxicology of abused drugs: a brief review. Mutagenesis, 13, 557–565.
152. Linnoila M and Hakkinen S, 1974. Effects of diazepam and codeine, alone and in combination with alcohol, on simulated driving. Clinical Pharmacology and Therapeutics, 15, 368–373.
153. Llewellyn N, Liley A and Moriarty A, 2000. Management of postoperative pain in infants and children. Current Anaesthesia & Critical Care, 11, 255–261.
154. Lo DS and Chua TH, 1992. Poppy seeds: implications of consumption. Medicine, Science, and the Law, 32, 296–302.
155. Lötsch J, 2005. Pharmacokinetic-pharmacodynamic modeling of opioids. Journal of Pain and Symptom Management, 29, S90–S103.
156. Madden JJ, Falek A, Shafer DA and Glick JH, 1979. Effects of opiates and demographic factors on DNA repair synthesis in human leukocytes. Proceedings of the National Academy of Sciences of the United States of America, 76, 5769–5773.
157. Mahler DA, Selecky PA, Harrod CG, Benditt JO, Carrieri-Kohlman V, Curtis JR, Manning HL, Mularski RA, Varkey B, Campbell M, Carter ER, Chiong JR, Ely EW, Hansen-Flaschen J, O'Donnell DE and Waller A, 2010. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest, 137, 674–691.
158. Mahmoudian M and Rahimi-Moghaddam P, 2009. The anti-cancer activity of noscapine: a review. Recent Patents on Anti-Cancer Drug Discovery, 4, 92–97.
159. Malaivijitnond S and Varavudhi P, 1998. Evidence for morphine-induced galactorrhea in male cynomolgus monkeys. Journal of Medical Primatology, 27, 1–9.
160. Martindale, 2005. The complete drug reference. Thirty-fourth edition, Pharmaceutical Press.
161. Martindale, 2010. The complete drug reference. Morphine; online. Pharmaceutical Press, London. Date of monograph revision: 20 August 2010. Available from www.medicinescomplete.com/mc/martindale/current/.
162. McEvoy GK, 1989. American hospital formulary service, drug information, Bethesda, American Society of Hospital Pharmacists.
163. McQuay HJ, 1989. Opioids in chronic pain. British Journal of Anaesthesia, 63, 213–226.
164. McQuay HJ, 1997. Opioid use in chronic pain. Acta Anaesthesiologica Scandinavica, 41, 175–183.
165. Mellin GW, 1964. Drugs in the First Trimester of Pregnancy and the Fetal Life of Homo Sapiens. American Journal of Obstetrics and Gynecology, 90, S1169–S1180.
166. Meny RG, Naumburg EG, Alger LS, Brill-Miller JL and Brown S, 1993. Codeine and the breastfed neonate. Journal of Human Lactation, 9, 237–240.
167. Merck, 2010. Fachinformation Merck, 2010. Morphin Merck Tropfen 0.5%/2%. Rote Liste Service GmbH, Berlin, Germany.
168. Merten C, Ferrari P, Bakker M, Boss A, Hearty A, Leclercq C, Lindtner O, Tlustos C, Verger P, Volatier JL and Arcella D, 2011. Methodological characteristics of the national dietary surveys carried out in the European Union as included in the European Food Safety Authority (EFSA) Comprehensive European Food Consumption Database. Food Additives and Contaminants. Part A, 28, 975–995.
169. Meyer UA, 2000. Pharmacogenetics and adverse drug reactions. Lancet, 356, 1667–1671.
170. Mignat C, Wille U and Ziegler A, 1995. Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sciences, 56, 793–799.
171. Mikus G, Somogyi AA, Bochner F and Eichelbaum M, 1991. Thebaine O-demethylation to oripavine: genetic differences between two rat strains. Xenobiotica, 21, 1501–1509.
172. Millgate AG, Pogson BJ, Wilson IW, Kutchan TM, Zenk MH, Gerlach WL, Fist AJ and Larkin PJ, 2004. Analgesia: morphine-pathway block in top1 poppies. Nature, 431, 413–414.
173. 3H]pseudomorphine in the rat. Biochemical Pharmacology, 21, 103–107.
174. Misra AL, Pontani RB and Mule SJ, 1974. Pharmacokinetics and metabolism of (3H) thebaine. Xenobiotica, 4, 17–32.
175. Mitchell ID, Carlton JB, Chan MY, Robinson A and Sunderland J, 1991. Noscapine-induced polyploidy in vitro. Mutagenesis, 6, 479–486.
176. Mittal R, Patil PA and Torgal SS, 2009. Screening of codeine, dextromethorphan & dextropropoxyphene for their genotoxicity in swiss albino mice. Indian Journal of Medical Research, 129, 676–680.
177. Moeller MR, Hammer K and Engel O, 2004. Poppy seed consumption and toxicological analysis of blood and urine samples. Forensic Science International, 143, 183–186.
178. Moffat AC, 1986. Clarke's isolation and identification of drugs in pharmaceuticals, body fluids, and post-mortem material. 2nd ed. London, The Pharmaceutical Press, 490–491.
179. Mogri M, Khan MI, Grant BJ and Mador MJ, 2008. Central sleep apnea induced by acute ingestion of opioids. Chest, 133, 1484–1488.
180. Morant R and Senn HJ, 1991. Pharmakokinetische Einflusse auf die Morphintoxizitat mit Fallbeispielen (Pharmacokinetic effects in morphine toxicity, with case examples). Schweizerische Rundschau fur Medizin Praxis/Revue suisse de medecine Praxis, 80, 719–722.
181. Morimoto S, Suemori K, Moriwaki J, Taura F, Tanaka H, Aso M, Tanaka M, Suemune H, Shimohigashi Y and Shoyama Y, 2001. Morphine metabolism in the opium poppy and its possible physiological function. Biochemical characterization of the morphine metabolite, bismorphine. The Journal of Biological Chemistry, 276, 38179–38184.
182. Mullis KB, Perry DC, Finn AM, Stafford B and Sadee W, 1979. Morphine persistence in rat brain and serum after single doses. The Journal of Pharmacology and Experimental Therapeutics, 208, 228–231.
183. Nasiraei-Moghadam S, Sahraei H, Bahadoran H, Sadooghi M, Salimi SH, Kaka GR, Imani H, Mahdavi-Nasab H and Dashtnavard H, 2005. Effects of maternal oral morphine consumption on neural tube development in Wistar rats. Brain Research. Developmental Brain Research, 159, 12–17.
184. Navarro G and Elliott HW, 1971. The effects of morphine, morphinone and thebaine on the EEG and behavior of rabbits and cats. Neuropharmacology, 10, 367–377.
185. Németh-Zámbori E, Jászberényi C, Rajhárt P and Bernáth J, 2011. Evaluation of alkaloid profiles in hybrid generations of different poppy (Papaver somniferum L.) genotypes. Industrial Crops and Products, 33, 690–696.
186. Nencini P, 1997. The rules of drug taking: wine and poppy derivatives in the ancient world. VI. Poppies as a source of food and drug. Substance Use & Misuse, 32, 757–766.
187. Nikolaev VO, Boettcher C, Dees C, Bunemann M, Lohse MJ and Zenk MH, 2007. Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors. The Journal of Biological Chemistry, 282, 27126–27132.
188. Ohlsson S, Holm L, Myrberg O, Sundstrom A and Yue QY, 2008. Noscapine may increase the effect of warfarin. British Journal of Clinical Pharmacology, 65, 277–278.
189. Oppel T, Thomas P and Wollenberg A, 2006. Cross-sensitization between poppy seed and buckwheat in a food-allergic patient with poppy seed anaphylaxis. International Archives of Allergy and Immunology, 140, 170–173.
190. Panasoff J, 2008. Poppy seed anaphylaxis. Journal of Investigational Allergology and Clinical Immunology, 18, 224–225.
191. Paturi M, Nieminen R, Reinivuo H and Ovaskainen M-L, 2006. Picture book of food portion sizes. Eds. Paturi M, Nieminen R, Reinivuo H and Oskvainen M-L. Publications of the National Public Health Institute B11/2006. Helsinki. 96 pp.
192. Paul BD, Dreka C, Knight ES and Smith ML, 1996. Gas chromatographic/mass spectrometric detection of narcotine, papaverine, and thebaine in seeds of Papaver somniferum. Planta Medica, 62, 544–547.
193. Pelders MG and Ros JJ, 1996. Poppy seeds: differences in morphine and codeine content and variation in inter- and intra-individual excretion. Journal of Forensic Sciences, 41, 209–212.
194. Penfield MP and Campbell AM, 1990. Experimental food science. 3rd Edition, Academic Press, 541 pp.
195. Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB and Sacerdote P, 2008. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Practice, 8, 287–313.
196. Peterson ME and Talcott PA, 2006. Small animal toxicology. Elsevier, 1232 pp.
197. th supplement.
198. Poeaknapo C, Schmidt J, Brandsch M, Drager B and Zenk MH, 2004. Endogenous formation of morphine in human cells. Proceedings of the National Academy of Sciences of the United States of America, 101, 14091–14096.
199. Poole PJ, Veale AG and Black PN, 1998. The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 157, 1877–1880.
200. Prajapati S, Bajpai S, Singh D, Luthra R, Gupta MM and Kumar S, 2002. Alkaloid profiles of the Indian land races of the opiumpoppy Papaver somniferum L. Genetic Resources and Crop Evolution, 49, 183–188.
201. Preininger VL, Vrublovsky P and Štastny VL, 1965. Alkaloidvorkommen in Mohnsamen (Papaver somniferum L.). Pharmazie, 20, 439–441.
202. Preininger V, 1972. The pharmacology and toxicology of the alkaloids from the plants of the family Papaveraceae. Acta Universitatis Palackianae Olomucensis Facultatis Medicae, 61, 213–254.
203. Rakicioglu N, Tek NA, Ayaz A and Pekcan G, 2009. Yemek ve besin fotograf katalogu. Hacettepe Universitesi, Saglik Bilimleri Fakultesi, Beslenme ve Diyetetik Bolumu, Ankara 2009. 132 pp.
204. Rauws AG, De Waal EJ and Van der Laan JW, 1997. Sense and non-sense in toxicity assessment of Medicinal Products. Advances in Drug Research, 30, 15–72.
205. Raye JR, Dubin JW and Blechner JN, 1977. Fetal growth retardation following maternal morphine administration-Nutritional or drug effect. Biology of the Neonate, 32, 222–228.
206. Reynolds JEF, 1989. Martindale, the extra pharmacopoeia, 29th ed. London, The Pharmaceutical Press. 1297–1299.
207. Richards ML and Sadée W, 1985. In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method. European Journal of Pharmacology, 114, 343–353.
208. Ritschel WA and Hammer GV, 1977. Pharmacokinetics of papaverine in man. International Journal of Clinical Pharmacology and Biopharmacy, 15, 227–228.
209. Rochholz G, Westphal F and Kuhlmann A, 2005. Erhöhte Morphingehalte in Mohnprodukten und deren Folgen. Getreidetechnologie, 59, 239–243.
210. Rochholz G, Westphal F, Wiesbrock UO and Schütz HW, 2004. Opiat-Nachweis in Urin, Blut und Haaren nach Verzehr mohnsamenhaltiger Backwaren. Blutalkohol, 41, 319–329.
211. Rote Liste, 2011. Rote Liste Service GmbH. Arzneimittelverzeichnis für Deutschland, Frankfurt/Main, Germany.
212. Rothman KJ, Fyler DC, Goldblatt A and Kreidberg MB, 1979. Exogenous hormones and other drug exposures of children with congenital heart disease. American Journal of Epidemiology, 109, 433–439.
213. RTECS (Registry of Toxic Effects of Chemical Substances), 2003. Thebaine, CAS No. 115-37-7. Document number RTQN0350000.
214. Sadraie SH, Kaka GR, Sahraei H, Dashtnavard H, Bahadoran H, Mofid M, Nasab HM and Jafari F, 2008. Effects of maternal oral administration of morphine sulfate on developing rat fetal cerebrum: a morphometrical evaluation. Brain Research, 1245, 36–40.
215. Sawant SG and Couch DB, 1995. Induction of micronuclei in murine lymphocytes by morphine. Environmental and Molecular Mutagenesis, 25, 279–283.
216. th ed. New York, Van Nostrand Reinhold, 944–945.
217. Saxen I, 1975. Association between oral clefts and drugs taken during pregnancy. International Journal of Epidemiology, 4, 37–44.
218. Schiff PL, 2002. Opium and its alkaloids. American Journal of Pharmaceutical Education, 66, 186–194.
219. Schönhofer B, Suchi S, Haidl P and Kohler D, 2001. Epidemiology concerning the effect of oral administration of morphine in patients with emphysema from pink puffer type. Medizinische Klinik, 96, 325–330.
220. Shah J and Mason WD, 1990. Pharmacokinetics of codeine after parenteral and oral dosing in the rat. Drug Metabolism and Disposition, 18, 670–673.
221. Shaw GM, Malcoe LH, Swan SH, Cummins SK and Schulman J, 1992. Congenital cardiac anomalies relative to selected maternal exposures and conditions during early pregnancy. European Journal of Epidemiology, 8, 757–760.
222. Shaw GM, Todoroff K, Velie EM and Lammer EJ, 1998. Maternal illness, including fever and medication use as risk factors for neural tube defects. Teratology, 57, 1–7.
223. Shuey DL, Gudi R, Krsmanovic L and Gerson RJ, 2007. Evidence that oxymorphone-induced increases in micronuclei occur secondary to hyperthermia. Toxicological Sciences, 95, 369–375.
224. Shukla S, Yadav HK, Rastogi A, Mishra BK and Singh SP, 2010. Alkaloid Diversity in Relation to Breeding for Specific Alkaloids in Opium Poppy (Papaver somniferum L.). Czech Journal of Genetics and Plant Breeding, 46, 164–169.
225. Siddiqui A, Haq S, Shaharyar S and Haider SG, 1995. Morphine induces reproductive changes in female rats and their male offspring. Reproductive Toxicology, 9, 143–151.
226. Sindrup SH, Hofmann U, Asmussen J, Mikus G, Brosen K, Nielsen F, Ingwersen SH and Broen Christensen C, 1996. Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. European Journal of Clinical Pharmacology, 49, 503–509.
227. Sproll C, Perz RC, Buschmann R and Lachenmeier DW, 2007. Guidelines for reduction of morphine in poppy seed intended for food purposes. European Food Research and Technology, 226, 307–310.
228. Sproll C, Perz RC and Lachenmeier DW, 2006. Optimized LC/MS/MS analysis of morphine and codeine in poppy seed and evaluation of their fate during food processing as a basis for risk analysis. Journal of Agricultural and Food Chemistry, 54, 5292–5298.
229. Srinivasan V, Wielbo D and Tebbett IR, 1997. Analgesic effects of codeine-6–glucuronide after intravenous administration. European Journal of Pain, 1, 185–190.
230. Stefano GB, Cadet P, Kream RM and Zhu W, 2008. The presence of endogenous morphine signaling in animals. Neurochemical Research, 33, 1933–1939.
231. Stolzenburg K, 2006. Neue morphinarme Sorte ermöglicht grossflächigen Anbau von Blaumohn. Landinfo, 3, 26–28.
232. Strumpf M, Köhler A, Zenz M, Willweber-Strumpf A, Dertwinkel R and Donner B, 1997. Opioide und Fahrtüchtigkeit. Schmerz, 11, 233–240.
233. Szabo B, Lakatos A, Koszegi T and Botz L, 2003. HPTLC and HPLC determination of alkaloids in poppies subjected to stress. Journal of Planar Chromatography-Modern Tlc, 16, 293–297.
234. Täschner K-L, 1994. Drogen und Straßenverkehr. Deutsche Apotheker Zeitung, 134, 31–39.
235. Täufel A, Ternes W, Tunger L and Zobel M, 1998. Lebensmittel-Lexikon L-Z; Band 2, Behr's Verlag, Hamburg.
236. Thajam D, Atkinson DE, Sibley CP and Lavender T, 2010. Is neonatal abstinence syndrome related to the amount of opiate used? Journal of Obstetric, Gynecologic, and Neonatal Nursing, 39, 503–509.
237. Thevis M, Opfermann G and Schanzer W, 2003. Urinary concentrations of morphine and codeine after consumption of poppy seeds. Journal of Analytical Toxicology, 27, 53–56.
238. Tiveron C, Hartley-Asp B, Johansson CJ and Pacchierotti F, 1993. Noscapine does not show aneugenic activity in mouse oocytes. Mutagenesis, 8, 311–315.
239. Trafkowski J, Musshoff F and Madea B, 2005. Positive Opiatbefunde nach Aufnahme von Mohnprodukten-Analytische Möglichkeiten zur Differenzierung einer Heroin- oder Mohnaufnahme. Blutalkohol, 42, 431–441.
240. Trenerry VC, Wells RJ and Robertson J, 1995. Determination of morphine and related alkaloids in crude morphine, poppy straw and opium preparations by micellar electrokinetic capillary chromatography. Journal of Chromatography. Part A, 718, 217–225.
241. Trescot AM, Datta S, Lee M and Hansen H, 2008. Opioid pharmacology. Pain Physician, 11, S133–153.
242. Tucci P, Palmery M, Piccolotti P, Pimpinella G, Valeri P and Romanelli L, 2008. Counteracting effect of papaverine on morphine inhibition of gastrointestinal transit in mice. Neurogastroenterology and Motility, 20, 958–965.
243. Tweats DJ, Blakey D, Heflich RH, Jacobs A, Jacobsen SD, Morita T, Nohmi T, O'Donovan MR, Sasaki YF, Sofuni T and Tice R, 2007. Report of the IWGT working group on strategies and interpretation of regulatory in vivo tests I. Increases in micronucleated bone marrow cells in rodents that do not indicate genotoxic hazards. Mutation Research, 627, 78–91.
244. Twycross R, 1990. Pain treatment in cancer patients. Schmerz, 4, 65–74.
245. US Department of Health and Human Services, 1992. Immunotoxicity of Morphine Sulfate in Female B6C3F1 Mice (CAS No. 64-31-3). NTP Report Number IMM92044.
246. US Department of Health and Human Services, 1996. Toxicology and carcinogenesis studies of codeine (CAS NO. 76-57-3) in F344/N rats and B6C3F1 mice (feed studies); NTP Technical Report 455, NIH Publication No. 96-3360.
247. Vainio A, Ollila J, Matikainen E, Rosenberg P and Kalso E, 1995. Driving ability in cancer patients receiving long-term morphine analgesia. Lancet, 346, 667–670.
248. Van de Wetering K, Zelcer N, Kuil A, Feddema W, Hillebrand M, Vlaming MLH, Schinkel AH, Beijnen JH and Borst P, 2007. Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides. Molecular Pharmacology, 72, 387–394.
249. Van der Laan JW and De Groot G, 1988. Changes in locomotor-activity patterns as a measure of spontaneous morphine withdrawal: no effect of clonidine. Drug Alcohol Dependence, 22, 133–140.
250. Van der Laan JW, Krajnc EI, Krajnc-Franken MA and Van Loveren H, 1995. Immunotoxicological screening of morphine and methadone in an extended 28 day study in rats. International Journal of Immunopharmacology, 17, 535–543.
251. Van der Laan JW, Loeber JG, De Groot G and Sekhuis VM, 1988. The concentration of morphine in serum of rats made dependent using a drug-admixed food method. Pharmacology, Biochemistry, and Behavior, 31, 123–128.
252. Van der Laan JW, Timmerman H and Van Loveren H, 1996. Comparison of the in vivo effects of morphine and methadone on natural killer cell activity in spleen, peritoneal cavity, and lungs in rats. International Journal of Immunopharmacology, 18, 401–407.
253. Van der Laan JW, Van 't Land CJ, Loeber JG and De Groot G, 1991. Validation of spontaneous morphine withdrawal symptoms in rats. Archives Internationales de Pharmacodynamie et de Therapie, 311, 32–45.
254. van Dorp EL, Morariu A and Dahan A, 2008. Morphine-6–glucuronide: potency and safety compared with morphine. Expert Opinion on Pharmacotherapy, 9, 1955–1961.
255. Vathy I, 2002. Prenatal opiate exposure: long-term CNS consequences in the stress system of the offspring. Psychoneuroendocrinology, 27, 273–283.
256. Vermeire A and Remon JP, 1999. Stability and compatibility of morphine. International Journal of Pharmaceutics, 187, 17–51.
257. Vree TB, van Dongen RT and Koopman-Kimenai PM, 2000. Codeine analgesia is due to codeine-6–glucuronide, not morphine. International Journal of Clinical Practice, 54, 395–398.
258. Walker JM, Farney RJ, Rhondeau SM, Boyle KM, Valentine K, Cloward TV and Shilling KC, 2007. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. Journal of Clinical Sleep Medicine, 3, 455–461.
259. Walsh CT and Levine RR, 1975. Studies of the enterohepatic circulation of morphine in the rat. The Journal of Pharmacology and Experimental Therapeutics, 195, 303–310.
260. Wang D and Teichtahl H, 2007. Opioids, sleep architecture and sleep-disordered breathing. Sleep Medicine Reviews, 11, 35–46.
261. Wasels R and Belleville F, 1994. Gas chromatographic-mass spectrometric procedures used for the identification and determination of morphine, codeine and 6–monoacetylmorphine. Journal of Chromatography. Part A, 674, 225–234.
262. Westphal F, Rochholz G, Gheorghiu D, Leinenkugel A and Schütz HW, 2006. Morphin und Codein im Blut nach Genuss von Mohnsamen-weiterführende systematische Untersuchungen. Blutalkohol, 43, 14–27.
263. WHO (World Health Organization), 1980. The dependence potential of thebaine; Report of a WHO Advisory Group. Bulletin on Narcotics, 32, 45–54. Available from www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1980-01-01_1_page006.html.
264. WHO (World Health Organization), 1997. WHO Drug Information Driving ability in cancer patients treated with morphine. 11, 11.
265. WHO (World Health Organization), 2007. WHO Forum on Reducing Salt Intake in Populations, Reducing salt intake in populations: report of a WHO forum and technical meeting, 5–7 October 2006, Paris, France.
266. WHO/IPCS (World Health Organization/International Program on Chemical Safety)), 2008. Uncertainty and data quality in exposure assessment. Harmonisation project document No. 6. ISBN 978 92 4 156376 5.
267. Williams J, Price CJ, Sleet RB, George JD, Marr MC, Kimmel CA and Morrissey RE, 1991. Codeine: developmental toxicity in hamsters and mice. Fundamental and Applied Toxicology, 16, 401–413.
268. Willmann S, Edginton AN, Coboeken K, Ahr G and Lippert J, 2009. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clinical Pharmacology and Therapeutics, 86, 634–643.
269. Winter CA and Flataker L, 1961. Toxicity studies on noscapine. Toxicology and Applied Pharmacology, 3, 96–106.
270. Wirth W and Gloxhuber C, 1981. Toxikologie-für Ärzte, Naturwissenschaftler und Apotheker; 3. Auflage, Georg Thieme Verlag.
271. Wittwer E and Kern SE, 2006. Role of morphine's metabolites in analgesia: concepts and controversies. The AAPS Journal, 8, E348–E352.
272. Wybran J, Appelboom T, Famaey JP and Govaerts A, 1979. Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes. Journal of Immunology, 123, 1068–1070.
273. Yanaura S, Nishimura T and Misawa M, 1983. Effects of codeine and morphine on the primary humoral immunity of the respiratory tract. Nippon Yakurigaku Zasshi, 81, 315–322.
274. Ye K, Ke Y, Keshava N, Shanks J, Kapp JA, Tekmal RR, Petros J and Joshi HC, 1998. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proceedings of the National Academy of Sciences of the United States of America, 95, 1601–1606.
275. Yeh SY and Woods LA, 1969. Physiologic disposition of N-C14-methyl-codeine in the rat. The Journal of Pharmacology and Experimental Therapeutics, 166, 86–95.
276. Yuan J, Dunnick JK, Barnes ER and Findlay JW, 1994. Codeine toxicokinetics in rats during a two-year dosed feed study. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 22, 14–20.
277. Yue QY, Alm C, Svensson JO and Sawe J, 1997. Quantification of the O- and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators. Therapeutic Drug Monitoring, 19, 539–542.
278. Yue QY, Svensson JO, Alm C, Sjoqvist F and Sawe J, 1989. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. British Journal of Clinical Pharmacology, 28, 639–645.
279. Zagon IS and McLaughlin PJ, 1984. An overview of the neurobehavioral sequelae of perinatal opioid exposure. In: Neurobehavioral Teratology. Ed Yanai J. Elsevier, New York, 197–234.
280. Ziegler J, Facchini PJ, Geissler R, Schmidt J, Ammer C, Kramell R, Voigtländer S, Gesell A, Pienkny S and Brandt W, 2009. Evolution of morphine biosynthesis in opium poppy. Phytochemistry, 70, 1696–1707.